Skeletal Muscle Relaxants for Acute Lumbar Back Pain
For acute lumbar back pain with muscle spasm, skeletal muscle relaxants are an appropriate short-term option (≤2 weeks), with no compelling evidence that any specific agent is superior to another, though you should avoid carisoprodol due to abuse potential and dantrolene due to hepatotoxicity risk. 1
Evidence-Based Recommendation
The American College of Physicians/American Pain Society guidelines establish that skeletal muscle relaxants provide moderate short-term pain relief for acute low back pain (duration <4 weeks) 1. These medications are FDA-approved for musculoskeletal conditions and work through diverse mechanisms, though some mechanisms remain unclear 1.
Which Muscle Relaxant to Choose
No single muscle relaxant demonstrates superior efficacy or safety over others 1, 2. However, the risk-benefit profiles vary substantially:
Preferred options:
- Cyclobenzaprine - Well-studied, effective when combined with NSAIDs 3
- Methocarbamol - Only approved muscle relaxant remaining after recent regulatory restrictions in Europe; demonstrated 44% complete pain relief vs 18% placebo 4
- Tizanidine - Well-studied for low back pain with 8 supporting trials 1, 2
Avoid or use with extreme caution:
- Carisoprodol - Metabolizes to meprobamate (associated with abuse, addiction, and overdose risk) 1
- Dantrolene - Black box warning for potentially fatal hepatotoxicity 1
- Chlorzoxazone and tizanidine - Associated with hepatotoxicity (generally reversible) 1
Duration and Expectations
- Treatment duration: Maximum 2 weeks - All efficacy trials evaluated therapy for ≤2 weeks (with one 3-week exception) 2
- Expected benefit: Moderate short-term pain relief at 2-4 days (RR 0.80 for not achieving pain relief) 2
- Functional improvement occurs but is generally smaller than pain relief 5
Combination Therapy
Muscle relaxants combined with NSAIDs provide clinically meaningful additional benefit compared to NSAIDs alone 6, 3. A 2025 meta-analysis showed combined therapy achieved superior global efficacy (RR: 0.62, p=0.01) without significantly increasing total adverse events 6.
Critical Safety Considerations
All skeletal muscle relaxants cause CNS adverse effects, primarily sedation 1:
- Total adverse events increase 1.5-fold vs placebo (RR: 1.50) 2
- CNS adverse events double (RR: 2.04-2.40) 2, 6
- Most events are self-limited; serious complications are rare 2
- Warn patients about sedation and avoid driving/operating machinery
Common Pitfall to Avoid
Do not use muscle relaxants for chronic low back pain - Evidence exists only for acute pain (<4 weeks duration). Only one low-quality trial evaluated chronic use, and it didn't report pain intensity 2. The 2020 JAGS guideline explicitly states these drugs "have no evidence of efficacy in chronic pain" and are "not favored for chronic pain" given adverse effect risks 7.
Clinical Algorithm
- Confirm acute LBP (<4 weeks) with muscle spasm component
- First-line: NSAIDs or acetaminophen (though recent evidence shows acetaminophen ineffective for acute LBP) 5
- Add muscle relaxant if inadequate response:
- Choose cyclobenzaprine, methocarbamol, or tizanidine
- Prescribe for ≤2 weeks maximum
- Counsel on sedation risk
- Reassess at 2-4 days - expect moderate improvement by this timepoint 2
- Discontinue if no benefit or consider non-pharmacologic therapy (spinal manipulation for acute LBP) 1
For Chronic LBP (>12 weeks)
Do not prescribe muscle relaxants - instead consider tricyclic antidepressants, duloxetine, or non-pharmacologic approaches (exercise therapy, spinal manipulation, acupuncture) 1.